TLSA — Tiziana Life Sciences Income Statement
0.000.00%
Last trade - 00:00
- $79.78m
- $62.03m
- 33
- 15
- 52
- 25
R2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 0 | — |
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 9.86 | 9.92 | 28 | 27.4 | 14.6 |
Operating Profit | -9.86 | -9.92 | -28 | -27.4 | -14.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.88 | -10 | -28.3 | -26.7 | -15.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.93 | -9.32 | -26.1 | -23.4 | -15.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.93 | -9.32 | -26.1 | -23.4 | -15.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.93 | -9.32 | -26.1 | -23.4 | -15.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.05 | -0.054 | -0.327 | -0.239 | -0.152 |